Company profile for Belite Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Belite Bio™ is a San Diego-based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. Developed from our RBP4 platform technology, our lead candidate, LBS-008, is currently in a Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received O...
Belite Bio™ is a San Diego-based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. Developed from our RBP4 platform technology, our lead candidate, LBS-008, is currently in a Phase I clinical trial for dry age-related macular degeneration and its juvenile form, Stargardt disease. LBS-008 has received Orphan Drug Designation in the US and Europe, as well as Rare Pediatric Disease Designation in the US.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
210 Merryfield Row San Diego CA, 92121
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://investors.belitebio.com/news-releases/news-release-details/new-hope-people-living-disease-once-deemed-untreatable-belite

PRESS RELEASE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197471/0/en/Belite-Bio-Announces-Proposed-Underwritten-Public-Offering-of-American-Depositary-Shares.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/10/3184490/0/en/Belite-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179223/0/en/Belite-Bio-to-Host-Webcast-on-November-10-2025-to-Discuss-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/11/02/3178795/0/en/Belite-Bio-Announces-UK-s-Medicines-and-Healthcare-Products-Regulatory-Agency-Agrees-to-Conditional-Marketing-Authorization-Application-Based-on-Interim-Analysis-Results-for-the-Tr.html

GLOBENEWSWIRE
02 Nov 2025

https://www.globenewswire.com/news-release/2025/10/29/3176352/0/en/Belite-Bio-to-Participate-in-the-Deutsche-Bank-ADR-Virtual-Investor-Conference.html

GLOBENEWSWIRE
29 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty